1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow CKD-704: new trials by email Literature Review of CKD-704 trials Research Report on CKD-704
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 213 | 2025-11-26 | 2025-12-19 |
Psoriasis (1)
Chong Kun Dang Pharmaceutical (1)
Poland (1)
2025 (1)